VC-backed Predictimmune raises £10m series-B

New investor BGF provided a £4m growth capital package as part of the round. PredictImmune will use the proceeds from the series-B to accelerate its global commercial expansion and support its expanding product pipeline.

Wellcome Trust led a £4.3m funding round for PredictImmune in 2018. Prior to that, Parkwalk Opportunities Fund led a £4.7m series-A funding round for the company in May 2017, with co-investment from Cambridge Enterprise and Wren Capital.

Parkwalk and Cambridge Enterprise both re-invested as part of the series-B.

Company
Founded in 2017, PredictImmune is a developer of prognostic tools to guide treatment of patients with immune-mediated diseases. The company's biomarker test was developed and validated in Crohn's disease and ulcerative colitis patients by researchers at the department of medicine at the University of Cambridge, part-funded by Wellcome. It is based in Cambridge.

People
BGF – Tim Rea, Nathan Heath (investors).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• UK / Ireland
• Healthcare
• BGF (Business Growth Fund)
• Venture